Study on Erdafitinib for Patients with Advanced Urothelial Cancer

Program Overview

The purpose of this study is to evaluate the safety and effectiveness of erdafitinib, a drug used to treat advanced urothelial cancer, both on its own and in combination with other treatments. The study will test erdafitinib with cetrelimab, an immunotherapy drug, and with chemotherapy drugs cisplatin and carboplatin. Researchers want to find the best dose and schedule for these treatments and see how well they work in patients who cannot take cisplatin and have not had previous treatment for their metastatic cancer.

Description

This study is open-label, meaning both the researchers and participants know which treatments are being given. It takes place at multiple medical centers. The study has two main parts: Phase 1b and Phase 2. In Phase 1b, researchers will determine the safest and most effective doses of erdafitinib when combined with cetrelimab and chemotherapy. Participants in this phase may have had previous treatments. In Phase 2, the study will compare erdafitinib alone to the combination of erdafitinib and cetrelimab in patients who have not had prior treatment for their metastatic cancer and cannot take cisplatin. The study includes a screening phase, a treatment phase, and a follow-up phase. Researchers will evaluate the effectiveness, safety, and how the body processes the drugs.

Eligibility Criteria

Locations